2022 | 2023e | 2024e | |
---|---|---|---|
Gewinn pro Aktie in EUR | -1,38 | -2,47 | -2,01 |
KGV | – | – | – |
PEG | – | – | – |
Dividende in EUR | – | – | – |
Dividendenrendite (%) | – | – | – |
Risiko- und Trendkennzahlen | |
---|---|
Gl. Durchschn. - 30T | 26,73 EUR |
RSL - 30T | 1,27 |
Vola - 30T | 34,91 |
Momentum - 30T | 1,41 |
Thema |
---|
Xencor-Antikörper-Biotechnologie · 26 Beiträge · 2 Bewertungen |
Wert | Perf. 1 Monat | Chance | Risiko |
---|---|---|---|
Bristol-Myers Squibb WKN 850501 | -5,14 % | ||
Gilead Sciences WKN 885823 | -9,21 % | ||
Moderna INC WKN A2N9D9 | -11,38 % | ||
Corteva WKN A2PKRR | -3,81 % | ||
Chugai Pharmaceutical WKN 857216 | -5,15 % | ||
Biogen WKN 789617 | -4,14 % | ||
BioNTech ADR WKN A2PSR2 | -12,60 % | ||
Illumina WKN 927079 | -1,50 % | ||
Alnylam Pharmaceuticals Inc WKN A0CBCK | -8,26 % | ||
BeiGene ADR WKN A1437N | +5,19 % |